| Literature DB >> 29267610 |
Wuhua Jiang1,2, Jiarui Xu1,2, Bo Shen1, Chunsheng Wang3, Jie Teng1,2,4, Xiaoqiang Ding1,2,4.
Abstract
OBJECTIVE: To assess the clinical value of four models for the prediction of cardiac surgery-associated acute kidney injury (CSA-AKI) and severe AKI which renal replacement therapy was needed (RRT-AKI) in Chinese patients.Entities:
Mesh:
Year: 2017 PMID: 29267610 PMCID: PMC5731314 DOI: 10.21470/1678-9741-2017-0116
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Predictors in each score.
| Prediction | Cleveland Score | Mehta Score | SRI Score | AKICS Score | ||||
|---|---|---|---|---|---|---|---|---|
| RRT-AKI | RRT-AKI | RRT-AKI | AKI | |||||
| Variable | Definition | Score | Definition | Score | Definition | Score | Definition | Score |
| Age | Varies | Varies | > 65 | 2.3 | ||||
| Race | Non-white | 2 | ||||||
| Gender | Female | 1 | ||||||
| Preoperative kidney function | SCr 1.2-2.1 mg/dL | 2 | SCr | Varies | GFR, 31-60 mL/min | 1 | Preoperative SCr > 1.2 mg/dL | 3.1 |
| SCr > 2.1 mg/dL | 5 | GFR ≤ 30 mL/min | 2 | |||||
| CHF | Yes | 1 | ||||||
| NYHA Class | 4 | 3 | 3 or 4 | 3.2 | ||||
| Diabetes | Preoperative capillary glucose > 140 mg/dL | 1.7 | ||||||
| COPD | Yes | 1 | Yes | 3 | ||||
| Recent MI (< 21 d) | Yes | 3 | ||||||
| LVEF | < 35% | 1 | ≤ 40% | 1 | ||||
| Previous surgery | Yes | 1 | Yes | 3 | Yes | 1 | ||
| Preoperative IABP | Yes | 2 | Yes | 1 | ||||
| Cardiogenic shock | Yes | 7 | ||||||
| Timing of surgery | Emergence | 2 | Non-selective | 1 | ||||
| CPB time | > 120 min | 1.8 | ||||||
| Postoperative CVP | > 14 cmH2O | 1.7 | ||||||
| LCOS | Yes | 2.5 | ||||||
| Type of surgery | CABG only | 0 | CABG only | 0 | Other than CABG | 1 | Combined surgery | 3.7 |
| Valve only | 1 | Aortic valve only | 2 | |||||
| CABG + valve | 2 | Aortic valve + CABG | 5 | |||||
| Mitral valve only | 4 | |||||||
| Mitral valve + CABG | 7 | |||||||
| Score range | 0-17 | 0-83 | 0-8 | 0-20 | ||||
AKI=acute kidney injury; RRT-AKI=AKI which renal replacement therapy is needed; CABG=coronary artery bypass grafting; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; CPB=cardiopulmonary bypass; CVD=cerebral vascular disease; CVP=central venous pressure by ICU admittance; DM=diabetes mellitus; eGFR=estimated glomerular filtration rate, as calculated based on the Cockcroft-Gault formulae for SRI score validation; GFR=glomerular filtration rate; IABP=intra-aortic balloon pump; LCOS=low cardiac output syndrome; LVEF=left ventricular ejection fraction; MI=myocardial infarction; NYHA=New York Heart Association; SCr=serum creatinine; SD=standard deviation
Characteristics of the patients in the validation cohort.
| Preoperative | Non-AKI (N=993) | AKI (n=594) | |
|---|---|---|---|
| Male | 542 (54.6%) | 434 (73.1%) | < 0.01 |
| Age, mean (SD), years | 56.8 (12.3) | 58.7 (11.7) | 0.08 |
| Kidney function | |||
| Serum creatinine, mean (SD) mg/dL | 0.83 (0.2) | 1.04 (0.40) | < 0.01 |
| eGFR, mean (SD) mL/min/1.73 m2 | 109.4 (30.4) | 85.9 (25.2) | < 0.01 |
| Comorbidities | |||
| Hypertension | 320 (32.2%) | 204 (34.3%) | 0.408 |
| DM | 136 (13.7%) | 60 (10.1%) | 0.04 |
| COPD | 0 | 0 | |
| CVD | 3 (0.3%) | 4 (0.7%) | 0.43 |
| Cardiac function | |||
| NYHA classification > 2 | 541 (54.5%) | 363 (61.1%) | < 0.01 |
| LVEF ≤ 35% | 101 (10.2%) | 147 (24.4%) | < 0.01 |
| Previous cardiac surgery | 9 (0.9%) | 8 (1.3%) | 0.454 |
| Intraoperative | |||
| Emergency | 2 (0.2%) | 0 | 0.531 |
| Procedure | |||
| Valve | 605 (60.9%) | 428 (72.1%) | < 0.01 |
| CABG | 342 (34.4%) | 133 (22.4%) | < 0.01 |
| Valve + CABG | 46 (4.6%) | 33 (5.6%) | < 0.01 |
| CPB time (min) | 89 (71,113) | 100 (79,124) | < 0.01 |
| Postoperative | |||
| LCOS | 3 (0.3%) | 13 (2.2%) | < 0.01 |
| CVP, mean (SD), cmH2O | 8.4 (2.7) | 10.9 (2.9) | < 0.01 |
| Prognosis | |||
| 28-day mortality | 8 (0.8%) | 36 (6.1%) | < 0.01 |
AKI=acute kidney injury; RRT-AKI=AKI which renal replacement therapy is needed; CABG=coronary artery bypass grafting; COPD=chronic obstructive pulmonary disease; CPB=cardiopulmonary bypass; CVD=cerebral vascular disease; CVP=central venous pressure by ICU admittance; DM=diabetes mellitus; eGFR=estimated glomerular filtration rate, as calculated based on the Cockcroft- Gault formulae for SRI score validation; LCOS=low cardiac output syndrome; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; SCr=serum creatinine; SD=standard deviation
Fig. 1ROC curve for the prediction of CSA-AKI of AKICS score.
Fig. 2ROC curves for the prediction of RRT-AKI of Cleveland score, Mehta score and SRI.
Comparison between predicted and observed outcomes for each score.
| AKI | RRT-AKI | |||
|---|---|---|---|---|
| AKICS (n=1585) | Cleveland (n=1587) | Mehta (n=1587) | SRI (n=1587) | |
| Predicted | 14% | 1.7% | 1.4% | 1.3-2.2% |
| Observed | 37.4% | 1.1% | 1.1% | 1.1% |
AKI=acute kidney injury
The predicted incidences of each outcome were derived from the origin papers.
| Abbreviations, acronyms & symbols | |
|---|---|
| AKI | = Acute kidney injury |
| AUROC | = Area under receiver operating characteristics curve |
| CABG | = Coronary artery bypass grafting |
| CPB | = Cardiopulmonary bypass |
| CSA-AKI | = Cardiac surgery-associated acute kidney injury |
| KDIGO | = Kidney Disease: Improving Global Outcomes |
| RRT-AKI | = Renal replacement therapy-acute kidney injury |
| SCr | = Serum creatinine |
| SD | = Standard deviation |
| Authors' roles & responsibilities | |
|---|---|
| WJ | Substantial contributions to the conception or design of the work; acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| JX | Substantial contributions to the conception or design of the work; acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| BS | Substantial contributions to the conception or design of the work; acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| CW | Final approval of the version to be published |
| JT | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| XD | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |